ClinicalTrials.gg
RecruitingNCT06385223Updated Aug 1, 2024

A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression

An interventional study of Beam F3 targeted accelerated iTBS and Individualized connectome-guided accelerated iTBS in Depression, sponsored by Institute of Mental Health, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Institute of Mental Health, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Depression with a site in Singapore — 14 open to participants now, 18 under way, none of them phase 3. Depression · Singapore.

Planned enrollment
17th of 25
70 · median 122
Started
2024
with 4 others
No phase
23 of 34
11 open now
Primary completion
2026-07
later than 7 of 17 live
Registered
20th of 34
by date
Lead sponsor
7 of 34
Institute of Mental Health, Singapore

Among the 34 studies in Depression with a site in Singapore, this one is the 17th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 20th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

14 of the 34 studies in Depression with a site in Singapore are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Depression with a site in Singapore, or all of them as a file.
02

Study summary

The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.

03

Conditions studied

  • Depression

Browse trials for

Keywords

  • neuronavigated
  • iTBS
  • Accelerated
  • RCT
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21 years.
  2. diagnosis of current Major Depressive Episode.
  3. Montgomery-Asberg Depression Rating Scale score of 20 or more.
  4. Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication.
  5. Able to give .

Exclusion criteria

Exclusion Criteria:

  1. psychotic disorder
  2. Drug or alcohol abuse or dependence (preceding 3 months).
  3. Rapid clinical response required, e.g., high suicide risk.
  4. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
  5. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.
  6. Pregnancy.
  7. Unsuitable for MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Beam F3 targeting of accelerated iTBS

    Patients will receive anatomically-guided (Beam F3) accelerated iTBS. Participants will receive an accelerated iTBS treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.

    Device: Beam F3 targeted accelerated iTBS

  • Experimental
    Individualized connectome-guided accelerated iTBS

    Patients will receive individualized connectome-guided accelerated iTBS. Participants will receive an accelerated iTBS treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.

    Device: Individualized connectome-guided accelerated iTBS

Interventions

  • DeviceBeam F3 targeted accelerated iTBS

    Magpro X100, Axilium Cobot, Localite camera

  • DeviceIndividualized connectome-guided accelerated iTBS

    Magpro X100, Axilium Cobot, Localite camera

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale

    Clinician rated depression rating scale, Scored 0 to 60, higher scores mean worse outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

Secondary outcomes

  1. Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report)

    Participant rated depression rating scale, scored 0-27, higher scores mean worse outcome

    Time frame: Baseline, daily during treatment (5 days), immediately post treatment, 1 month and 3 months post intervention

  2. Montreal Cognitive Assessment (MoCA)

    global cognitive functioning, scored 0-30, higher score means better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

  3. EQ-5D (EuroQol)

    Quality of life scales, scored 0-100, higher scores mean better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

  4. Quality of Life Enjoyment and Satisfaction Questionnaire Short form (Q-LES-QS-SF)

    Quality of life scales, scored 14-70, higher score means better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

Other outcomes

  1. TMS induced changes in resting-fMRI functional connectivity

    The investigators will also perform additional exploratory posthoc analyses by analysing brain imaging changes before and after TMS

    Time frame: Baseline, immediately post treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
Apr 25, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06385223
Lead sponsor
Institute of Mental Health, Singapore
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jul 1, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 1, 2024

Study contacts

Phern Chern Tor, MBBS
Contact
phern_chern_tor@imh.com.sg
63892000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion